An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Pharmacokinetic Study Comparing Microactive Pyrroloquinoline Quinone 40mg SR Capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka With Pyrroloquinoline Quinone 40mg IR capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka In Healthy Adult Human Male And Female Subjects Under Fed Conditions
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- To assess the Pharmacokinetic Study of Comparing Microactive Pyrroloquinoline Quinone 40mg SR Capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka With Pyrroloquinoline Quinone 40mg IR capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka In Healthy Adult Human Male And Female Subjects Under Fed Conditions
研究概览
简要总结
At least 08 number of healthyadult human 04 male and 04 female subjects will be recruited to evaluate thePharmacokinetic of Test product with the Reference product
As per the discretion of theInvestigator a sufficient number of stand by subjects will be includedadditionally to ensure successful dosing of 08 subjects in period I alone
In each period subjects will behoused in the clinical facility for at least 11 00 hours pre dose to 24 00hours post dose
A washout period of at least 07days will be maintained between each dosing period
In each period after an overnightfasting of at least 08 00 hours prior to Standard Light Breakfast
In the morning Standard LightBreakfast will be provided 2.00 hours before dosing
After consumption of breakfastin the morning a single oral dose of either the test product T or referenceproduct R will be administered as per the randomization schedule with 240 mL ofdrinking water at ambient temperature
Blood pressureradial pulse rate body temperature andwellbeing status will be enquired and recorded at and 00 00 hour within 75minutes of before dosing and at 01 00 03 00 06 00 and 11 00 hours plus or minus60 minutes post dose
Monitoring foradverse events will be done throughout the study period in clinical phase
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 45.00 Year(s)（—）
- 性别
- All
入选标准
- •Normal healthy adult human male and female subjects of age between 18 to 45 years and Body Mass Index ranges between 18 50 kg per m2 to 30 00 kg per m2 according to the formula BMI weight kg per height m2 Subjects who have no evidence of underlying disease during screening and check in and whose screening is performed within 21 days of check in Subjects whose screening laboratory values are within normal limits are considered by the physician or principal clinical investigator to be of no clinical significance Healthy as documented by the medical history physical examination including but not limited to an evaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervous system and vital sign assessments Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinical laboratory assessments Willing to consume non vegetarian diet and Standard Light breakfast Willing to comply with all requirements of this study protocol as well as instructions from the study personnel Non smokers Generally healthy as documented by gynaecological examination and breast examination period I only Healthy individuals who were not currently undergoing treatment for any serious disease Those with a score of 13 or higher in the Activities of Daily Living ADL test questionnaire conducted in advance Females of childbearing potential must have a negative serum pregnancy test performed within 21 days prior to the initiation of the study and a negative urine pregnancy test prior to check in for each period If the subject is female currently not pregnant not lactating or not attempting to become pregnant for 4 weeks before the screening visit throughout the duration of the study and 3 weeks after the subject s last study related visit for eligible subjects only if applicable has a negative serum pregnancy test and is of non childbearing potential defined as greater or equal to 01 year post menopausal no menstrual period for at least 12consecutive months without any other medical cause Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy or is of childbearing potential willing to commit to using a consistent and acceptablemethod of birth control as defined below for the duration of the study double barrier methods condoms cervical cap diaphragm and vaginal contraceptivefilm with spermicide intrauterine device IUD with a low failure rate of less than 1 percentage per year or is of childbearing potential and not sexually active willing to commit to using a consistentand acceptable method of birth control as defined above for the duration of thestudy in the event the subject becomes sexually active.
排除标准
- •Evidence of allergy or known hypersensitivity to Pyrroloquinoline Quinone or its inactive ingredients Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre existing gallbladder disease Any major illness in the last three months or any significant ongoing chronic medical illness Renal or liver impairment Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis History of alcohol addiction or abuse Consumption of caffeine and /or xanthine containing products ie coffee tea chocolatecaffeine containing sodas colas etc cigarettes and tobacco containing products for atleast 48.00 hours prior to check in and throughout the entire study Consumption of alcohol and its products grapefruit and or its juice and poppycontaining foods within 48.00 hours prior to clinic admission and throughout theentire study Subjects who have taken any prescription medications within 14 days prior to studycheck-in and throughout the study and any over the counter medicinal productsherbal medications within 07 days prior to study check in and throughout the study Subjects who have taken any unusual diet for whatever reason eg low salt for 48.00hours prior to dosing and throughout the study Subject who had participated in any other study within the 90 days of check in History of difficulty in swallowing History of difficulty in accessibility of veins Positive results for urine screen of drugs of abuse Marijuana THC amphetamine AMPbarbiturates BAR cocaine COC benzodiazepines BZD and morphine MOR in urineprior to check in of each period Positive results for alcohol test prior to check-in of each period Any blood donation excess blood loss within 90 days of check-in Ingestion of any hormonal agent at any time within 14 days prior to the start of thestudy check-in Use of hormone replacement therapy for a period of 06 months prior to dosing Female subjects demonstrating a positive pregnancy screen Female subjects who are currently lactating Females are likely to become pregnant during the course of the study.
结局指标
主要结局
To assess the Pharmacokinetic Study of Comparing Microactive Pyrroloquinoline Quinone 40mg SR Capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka With Pyrroloquinoline Quinone 40mg IR capsules Manufactured by Kalpatharu Naturals Pvt Ltd U 76 Hootagalli Industrial Area Mysore 570018 Karnataka In Healthy Adult Human Male And Female Subjects Under Fed Conditions
时间窗: 16 time points | 00 00 hrs 00 50 hrs 01 00 hrs 01 50 hrs 02 00 hrs 02 25 hrs 02 50 hrs 02 75 hrs 03 00 hrs 03 25 hrs 03 50 hrs 04 00 hrs 06 00 hrs 08 00 hrs 10 00 hrs and 12 00 hrs
次要结局
- To monitor the safety and tolerability of test product comparing with the reference product in healthy adult human male and female subjects under fed conditions(16 time points)